Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Carl Zeiss adds glaucoma data to StratusOCT:

This article was originally published in Clinica

Executive Summary

Carl Zeiss Meditec has launched a new version of its retinal imaging instrument StratusOCT in Europe and Asia with an enhancement that can help improve glaucoma diagnosis. The latest device incorporates retinal fibre layer (RNFL) normative data, which provides clinicians with the normal ranges of retinal layer thickness, against which they can judge the measurements from their patients. This new version is currently awaiting FDA approval in the US. StratusOCT, an optical coherence tomographer, is the first instrument to provide cross-sectional imaging of the retina using ordinary light instead of X-rays, according to the Dublin, California firm. Glaucoma affects three million people in the US and is the leading cause of preventable blindness.

You may also be interested in...



Sanofi Grapples With Pandemic, Growing Clinical Trials, Implementing Acquisitions

Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.

ATAI Raises $125m Series C To Expand The Boundaries In Mental Health

The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.

10 Predictions On How Health Policy Could Change Under A Biden Presidency

Health policy changes that President-elect Joe Biden will likely make during his four-year term include Medicaid expansion and a greater reliance on medical science, among others, experts say.

Topics

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel